CA
NZ
UK
AU
IND
US
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) secured exclusive U.S. rights to PharmAla's patented non-racemic MDMA formulation ALA-002, giving Jupiter a psychedelic neuropsychiatric asset.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares closed up 22% at $13.45 after the company reported a widened Q2 net loss of $23.8 million as collaboration revenue declined following reduced recognition from CSL Seqirus.
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) will merge with Ambros Therapeutics in an all-stock transaction to form Nasdaq-listed Ambros Therapeutics, shifting focus to neridronate for CRPS-1.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares ticked higher in pre-market trading after the company announced that its investigational drug imsidolimab received Orphan Designation from the European Commission for the treatment of Generalized Pustular Psoriasis, a severe and potentially life-threatening inflammatory skin disease. The designation marks …
Virtuix Holdings Inc. (NASDAQ:VTIX) was featured in a Bloomberg Television broadcast on August 22, spotlighting the company's immersive virtual reality technology alongside two other public companies addressing different market opportunities. The sponsored programming segment aired across Bloomberg Television in the United States, Latin America, …
SI-BONE, Inc. (NASDAQ:SIBN) shares climbed further in pre-market trading, extending recent momentum as investors weigh a series of heavy insider stock sales against strong underlying fundamentals following the company's second-quarterEarningsbeat. The stock's advance follows a string of bullish analyst actions, including initiating coverage with …
SafeSpace Global Corporation (OTCID:SSGC) was featured in a Bloomberg Television broadcast on August 22, highlighting the company's artificial intelligence-powered physical security platform designed to help schools, senior-living facilities, and other organizations identify potential threats earlier. The sponsored programming segment aired alongside features on two …
REGENXBIO Inc. (NASDAQ:RGNX) shares dropped sharply in pre-market trading after the U.S. Food and Drug Administration placed a clinical hold on RGX-121, the company's investigational gene therapy for Mucopolysaccharidosis type II, also known as Hunter Syndrome. The hold followed the discovery of asymptomatic spine …
Atrium Therapeutics, Inc. (NASDAQ:RNA) shares fell in pre-market trading following the company's disclosure of inducement equity grants awarded to a newly hired non-executive employee under its 2026 Employment Inducement Incentive Award Plan. The grants, a standard practice for attracting talent at growing biotechnology companies, …
BioVie Inc. (NASDAQ:BIVI) shares declined in pre-market trading even after the company was featured in a Bloomberg Television broadcast highlighting its investigational Parkinson's disease therapy, bezisterim. The segment, distributed through a sponsored financial media platform, spotlighted the company's Phase 2 SUNRISE-PD trial results alongside …
Please wait processing your request...